Efficacy and Safety of Tolvaptan in Heart Failure Patients with Renal Impairment and Volume Overload Despite the Standard Treatment with Conventional Diuretics

Trial Profile

Efficacy and Safety of Tolvaptan in Heart Failure Patients with Renal Impairment and Volume Overload Despite the Standard Treatment with Conventional Diuretics

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Nov 2015

At a glance

  • Drugs Tolvaptan (Primary) ; Diuretics; Furosemide
  • Indications Heart failure; Renal impairment
  • Focus Therapeutic Use
  • Acronyms K-STAR
  • Most Recent Events

    • 02 Sep 2015 Primary endpoint has been met. (Urinary output), according to an abstract presented at the the ESC Congress 2015: Annual Congress of the European Society of Cardiology
    • 02 Sep 2015 Results presented at the ESC Congress 2015: Annual Congress of the European Society of Cardiology
    • 03 Dec 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top